In the United States, an approved biosimilar can be designated as “interchangeable.”

The United States Food and Drug Administration expects clinical data to support a demonstration of interchangeability.

Clinical studies that support interchangeability should be designed primarily to evaluate if clinical performance is altered by multiple switching between a reference product and its biosimilar and whether such switching will result in differences in pharmacokinetics or immunogenicity profiles.